Publication Results (27)

• Adherence to osteoporosis pharmacotherapy is underestimated using days supply values in electronic pharmacy claims data

  Burden AM, Paterson JM, Gruneir A, Cadarette SM. Pharmacoepidemiol Drug Saf. 2015; 24(1):67-74. Epub 2014 Oct 21.

• Trends in heart failure outcomes and pharmacotherapy: 1992 to 2000

  Lee DS, Mamdani MM, Austin PC, Gong Y, Liu PP, Rouleau JL, Tu JV. Am J Med. 2004; 116(9):581-9.

• Trends in selection and timing of first-line pharmacotherapy in older patients with Type 2 diabetes diagnosed between 1994 and 2006

  Foster PD, Mamdani MM, Juurlink DN, Shah BR, Paterson JM, Gomes T. Diabet Med. 2013; 30(10):1209-13. Epub 2013 Apr 16.

• Risk-treatment mismatch in the pharmacotherapy of heart failure

  Lee DS, Tu JV, Juurlink DN, Alter DA, Ko DT, Austin PC, Chong A, Stukel TA, Levy D, Laupacis A. JAMA. 2005; 294(10):1240-7.

• Resident-level predictors of dementia pharmacotherapy at long-term care admission: the impact of different drug reimbursement policies in Ontario and Saskatchewan

  Maclagan LC, Bronskill SE, Campitelli MA, Yao S5, Dharma C, Hogan DB, Herrmann N, Amuah JE, Maxwell CJ. Can J Psychiatry. 2020; Apr 10 [Epub ahead of print]. DOI: https://doi.org/10.1177/0706743720909293

• Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction

  Rasmussen JN, Chong A, Alter DA. JAMA. 2007; 297(2):177-86.

• Osteoporosis quality indicators using healthcare utilization data

  Cadarette SM, Jaglal SB, Raman-Wilms L, Beaton DE, Paterson JM. Osteoporos Int. 2011; 22(5):1335-42. Epub 2010 Jun 25.

• Subgroups, treatment effects, and baseline risks: some lessons from major cardiovascular trials

  Parker AB, Naylor CD. Am Heart J. 2000; 139(6):952-61.

• Osteoporosis management and fractures in the Métis of Ontario, Canada

  Jandoc R, Jembere N, Khan S, Russell SJ, Allard Y, Cadarette SM. Arch Osteoporos. Epub 2015 Apr 25.

• Effectiveness of community-wide and individual high-risk strategies to prevent diabetes: a modelling study

  Manuel DG, Rosella LC, Tuna M, Bennett C, Stukel TA. PLoS One. 2013; 8(1):e52963. Epub 2013 Jan 4.

• Relationship between cardiac rehabilitation and survival after acute cardiac hospitalization within a universal health care system

  Alter DA, Oh PI, Chong A. Eur J Cardiovasc Prev Rehabil. 2009; 16(1):102-13.

• Medical comorbidity, acute medical care use in late-life bipolar disorder: a comparison of lithium, valproate, and other pharmacotherapies

  Rej S, Yu C, Shulman K, Herrmann N, Fischer HD, Fung K, Gruneir A. Gen Hosp Psychiatry. 2015; 37(6):528-32. Epub 2015 Jul 11.

• Screening and treatment for osteoporosis after stroke: results from the Ontario stroke registry

  Kapoor E, Austin PC, Alibhai SMH, Cheung AM, Cram P, Casaubon LK, Fang J, Porter J, Smith EE, Prager M, Kapral MK. Stroke. 2019; 50(6):1564-6. Epub 2019 Apr 25. DOI: 10.1161/STROKEAHA.118.024685.

• Warfarin therapy and risk of hip fracture among elderly patients

  Mamdani M, Upshur RE, Anderson G, Bartle B, Laupacis A. Pharmacotherapy. 2003; 23(1):1-4.

• The challenges of prescribing drug therapy to older people

  Dergal J, Rochon P. Geriatr Aging. 2001; 4(1):7-8.

• Universal drug coverage and socioeconomic disparities in major diabetes outcomes

  Booth GL, Bishara P, Lipscombe LL, Shah BR, Feig DS, Bhattacharyya O, Bierman AS. Diabetes Care. 2012; 35(11):2257-64. Epub 2012 Aug 13.

• Secondary prevention treatment after acute stroke in older South Asian, Chinese and other Canadians: a retrospective data analysis

  Khan NA, McAlister FA, Pilote L, Palepu A, Quan H, Hill MD, Fang J, Kapral MK. CMAJ Open. 2017; 5(3):E702-9.

• Examining exposure misclassification of oral bisphosphonate therapy and the associated fracture risk: a cohort study

  Burden AM, Gruneir A, Paterson JM, Cadarette SM. Adv Pharmacoepidemiol Drug Saf. 2015; 4:4.

• Thromboembolic prophylaxis in moderate-risk patients undergoing elective abdominal surgery: decision and cost-effectiveness analyses

  Mamdani MM, Weingarten CM, Stevenson JG. Pharmacotherapy. 1996;16(6):1111-27.

• CCORT/CCS quality indicators for congestive heart failure care

  Lee DS, Tran C, Flintoft V, Grant FC, Liu PP, Tu JV; Canadian Cardiovascular Outcomes Research Team/Canadian Cardiovascular Society Heart Failure Quality Indicator Panel. Can J Cardiol. 2003; 19(4):357-64.

• Investigating the determinants of decreasing postmyocardial infarction mortality: an analysis of in-hospital data from 1992 and 1997

  Daneman N, Austin PC, Tu JV. Can J Cardiol. 2001; 17(7):771-6.

• The risk of postpartum hemorrhage with selective serotonin reuptake inhibitors and other antidepressants

  Salkeld E, Ferris LE, Juurlink DN. J Clin Psychopharm. 2008; 28(2):230-4.

• From pharmaco-therapy to pharmaco-prevention: trends in prescribing to older adults in Ontario, Canada, 1997-2006

  Bajcar JM, Wang L, Moineddin R, Nie JX, Tracy CS, Upshur RE. BMC Fam Pract. 2010; 11:75.

• Impact of the JUPITER trial on statin prescribing for primary prevention

  Teng JF, Gomes T, Camacho X, Grundy S, Juurlink DN, Mamdani MM. Pharmacotherapy. 2014; 34(1):9-18. Epub 2013 Aug 12.

• Modelling preventive effectiveness to estimate the equity tipping point: at what coverage can individual preventive interventions reduce socioeconomic disparities in diabetes risk?

  Manuel DG, Ho TH, Harper S, Anderson GM, Lynch J, Rosella LC. Chronic Dis Inj Can. 2014; 34(2-3):94-102.

• Varenicline and risk of self-harm: a nested case-control study

  Tadrous M, Martins D, Yao Z, Mamdani MM, Juurlink DN, Gomes T, Antoniou T. PLoS One. 2016; 11(9):e0163681.

• Angiotensin receptor blockers vs. angiotensin converting enzyme inhibitors and acute coronary syndrome outcomes in elderly patients: a population-based cohort study (UMPIRE study results)

  Verma S, Mamdani MM, Al-Omran M, Melo M, Rouleau JL. J Am Soc Hypertens. 2007; 1(4):286-94.